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Purpose: To measure the effectiveness of a tailored decision aid to help women make 
informed decisions about genetic testing for breast/ovarian cancer risk. Methods: 145 women 
were randomized to receive the decision aid or a control pamphlet at the end of their first 
genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week 
and 6 months post-consultation. Results: While the decision aid had no effect on informed 
choice, post-decisional regret or actual decision, the trial showed that women who received 
the decision aid had higher knowledge levels and felt more informed about genetic testing 
than women who received the control pamphlet (χ2(2)= 6.82; P=0.033;  χ2(1)=4.86; P=.028 
respectively). The decision aid also helped women who did not have blood drawn at their first 
consultation to clarify their values with regards to genetic testing (χ2(1)=5.27; P=.022). 
Women who received the decision aid were less likely to share the information with other 
family members than women in the control condition (χ2(1)=8.78; P=.003). Conclusions: 
Decision aids are an effective decision-support strategy for women considering genetic testing 
for breast/ovarian cancer risk, and are most effective before the patient has made a decision, 
which is generally at the point of having blood drawn.  
 





Genetic testing for cancer risk can empower individuals to make informed choices about 
health management for the future. In many countries, women with a strong family history of 
breast and/or ovarian cancer can be tested for a mutation in one of two breast and ovarian 
cancer-related genes (BRCA1 and BRCA2). This knowledge enables women identified as 
carriers of a breast/ovarian cancer-related mutation to significantly reduce their risk of 
developing cancer through increased use of screening and preventative measures.1-4 
Conversely, proven non-carriers of BRCA mutations, and their offspring, are only at 
population risk of developing cancer and do not need to consider the increased surveillance 
and preventative options offered to carriers, saving the costs, concerns and inconvenience of 
unnecessary procedures.5   
 
There are generally two stages involved in cancer genetic testing. The first involves the 
collection of blood from an affected individual for a ‘mutation search’, whereby the BRCA1 
and BRCA2 genes are examined for pathogenic mutations. Genetic testing in individuals 
already affected by cancer can help to clarify a woman’s future risk of developing further 
breast and/or ovarian cancers. Mutation search however is often inconclusive because a 
causative mutation cannot always be found despite a strong family history. If a causative 
mutation is identified in an affected family member, then other adult at-risk family members 
can be offered a ‘predictive’ test to find out if they carry the family-specific mutation. 
Predictive testing in unaffected women is significant because it predicts her future risk of 
developing breast and ovarian cancer. Women who carry a germline mutation in a BRCA1 or 
BRCA2 gene have a lifetime risk of developing breast cancer of 50-85% and a lifetime risk of 
developing ovarian cancer of 15-65%,6,7 with her offspring having a 50% chance of carrying 
the same mutation.  
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One problem of genetic testing for cancer risk is that it is not a failsafe means of determining 
women’s chances of developing cancer. Inconclusive results or results of uncertain 
significance are common, and the psychological impact of going through the genetic testing 
process and receiving an inconclusive result is not yet well understood.8-10 It is also crucial for 
women who receive a positive test result to understand that it is not possible to predict when, 
where and indeed if they will ever develop cancer. For non-carriers, it is similarly important 
for them to understand that it is still possible for them to develop breast and/or ovarian cancer, 
despite a negative predictive genetic testing result.  
 
A decision aid for women considering genetic testing 
A decision about genetic testing for cancer risk is a ‘preference-sensitive’ decision, and the 
best choice for each patient is usually made by weighing up how they value the benefits of 
genetic testing compared to its potentially harmful implications.11,12 Given the complexity of 
the potential benefits and limitations of genetic testing for breast/ovarian cancer risk, a 
decision aid (DA) for women considering genetic testing was developed. Decision aids are 
specifically aimed at facilitating decision-making, and are designed to improve patients’ 
understanding of the potential benefits and risks of their different options, as well as assist 
patients to consider the personal importance they place on each of these options.13 The 
development and evaluation of the DA was theoretically guided by the frameworks developed 
by O’Connor and colleagues, which provide guidance on the decision aid development 
process, selection of study measures, specification of hypotheses, and suggested study 
outcomes for the evaluation the effectiveness of decision aids.14-16 
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The breast/ovarian cancer DA provides balanced information about three options: doing 
nothing (ie. not undergoing genetic testing), undergoing genetic testing or deciding to 
consider the issue at a later date. The topics in the 40-page DA include background 
information about cancer and cancer-related genes, a description of the genetic testing 
process, possible test results and a discussion of the potential impact of genetic testing on the 
individual and their family. The DA explains the evidence available on cancer risks and 
genetic testing, as well as explaining the differences between mutation search and predictive 
testing and the potential benefits, risks and limitations of testing. The decision aid includes the 
chances of receiving different types of test results (true and false, and positive and negative 
results, as well as inconclusive results), and describes the next steps for the patient based on 
their result. Where possible, visual diagrams are used in conjunction with words and numbers 
to describe probabilities, and diagrams allow clinicians to tailor the DA to the patient by 
circling the risk levels appropriate for their age group. The DA concludes with two patient 
stories, and a blank personal worksheet (values clarification exercise) is provided for 
individuals to list the benefits and risks of genetic testing in their situation. The worksheet 
also asks individuals to rate the importance of each risk and benefit as a ‘leaning’ towards or 
against having the genetic test by allocating 0-5 stars to each listed item. A more detailed 
description of the DA is provided in Wakefield et al.17 
 
Aims and hypotheses 
This study aimed to evaluate a DA for women considering genetic testing for breast and 
ovarian cancer risk in a randomized controlled trial. It was hypothesized that compared to 
women receiving the standard best practice, a general educational pamphlet, those who 
received the purpose designed DA would have: 
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a) decreased decisional conflict about genetic testing (primary outcome);  
b) increased knowledge about genetic testing; and 
c) an increased rate of informed choice. 
 
MATERIALS AND METHODS 
Sample 
The research sample included women (both affected and unaffected by cancer) who 
approached one of five Australian familial cancer clinics participating in this study. Women 
are referred to Australian familial cancer clinics by general practitioners, oncologists and 
surgeons who become aware of, or concerned about, a woman’s family history of cancer. 
While some procedures vary across clinics, most clinics conduct a brief telephone interview 
with potential patients prior to their appointment in order to ascertain a brief verbal family 
history, and provide the patient with information about further details they need to bring to 
their appointment.  
 
To be eligible to participate in the study, women were:  
(i) Eligible for genetic testing in Australia, that is, women with a family history 
consistent with a dominantly inherited hereditary breast/ovarian cancer syndrome 
who have an affected, living relative willing to provide a blood sample;18,19
(ii) able to give informed consent;  
  
(iii) able to read English; and  
(iv) aged 18 years or older.   
 
Males were excluded due to the low numbers of men currently attending familial cancer 
clinics, making meaningful statistical analysis of responses difficult. Affected women 
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considering predictive testing were also excluded due to differing informational needs 




The human research ethics committee of each clinic approved the study and informed consent 
was obtained from all participants. A randomized controlled trial was used to compare the 
efficacy of the DA with an educational pamphlet currently used in many clinics in Australia.20 
The 4-page pamphlet is comparable to the DA in describing hereditary breast and ovarian 
cancer, its pattern of inheritance, and the general benefits and risks of genetic tests. The 
pamphlet does not however include characteristic DA features, such as balanced information 
describing different decision options, patient stories and a values clarification exercise.21
Randomization at the end of genetic counseling minimized the potential impact of the 
knowledge of randomization status on the course of the consultation. Randomization after the 
  
 
Recruitment of participants 
Figure 1 presents a flowchart of the recruitment process. Consent to participate in the study 
was sought by clinic staff following each eligible patient’s initial consultation. Those who 
agreed were given a pre-randomized envelope containing the DA or the control pamphlet, a 
consent form, the first questionnaire and a reply-paid envelope. They were asked to complete 
and return the questionnaire within 7 days after counseling whenever possible. The 
questionnaire was clearly marked “Please read your genetic testing information booklet before 




patient had left the consultation (which would have ensured blindness of the clinician to the 
intervention assignment) was not possible because some clinicians expressed a preference for 
being able to tailor the DA to the patient by entering personalized information (such as risk 
estimations based on family history) into the DA. Indeed, previous research has shown that 
patients at high risk of developing cancer prefer tailored over stand-alone-tools.22,23
(1) Type of genetic test: Clinicians indicated which type of genetic test the woman was 
considering (mutation search or predictive testing). For predictive testing, the clinician 
indicated whether a family-specific mutation had already been identified, and if not, 
whether mutation search had commenced in the family. 
  
 
-------------------- Insert Fig. 1 about here---------------------------------------------------------------- 
 
Participants were randomized according to family-wise randomization. That is, all patients 
who were the first of their family to attend the clinic were randomly allocated to the control or 
DA condition. Subsequent members of the same family attending the same clinic were then 
assigned to the same condition as their other family members, in order to prevent potential 
contamination across groups. 
 
Six months post-consultation, a second questionnaire was mailed to assess any longer-term 
effect of the DA. Reminder letters and phone calls were made as appropriate. 
 
Measures  
Staff at familial cancer clinics provided the following data.  
(2) Participant’s disease status: Women were classified as either affected or unaffected 
by breast/ovarian cancer, and if unaffected, their mutation carrier risk was given.   
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(3) Blood drawn: Clinic staff noted whether or not blood was drawn on the day of the first 
consultation. This was a critical variable, as it determined whether the participant was 
able to read the DA or control pamphlet before having blood drawn for testing. In 
most Australian clinics it is standard practice to allow a ‘cooling off’ period after the 
patient’s first consultation before drawing blood for a predictive genetic test (usually 
at a separate appointment two weeks later). In some clinics however, and in other 
individual cases (for example, if the patient has traveled a long distance or the patient 
has a good background knowledge before clinic attendance), blood may be drawn 
immediately after the first consultation at the patient’s request.  
(4) Participant’s decision: Clinicians reported the genetic testing decision they felt was 
the best choice for the woman at the end of the consultation (response options 
included: ‘In my opinion the best choice for this patient would be to: ‘undergo genetic 
testing’, ‘not undergo genetic testing’, or ‘defer their decision to a later date’). The 
concordance between clinician opinion and the patient’s decision after the first 
consultation was rated as a dichotomous variable (‘patient and clinician agreed’ and 
‘patient and clinician disagreed’ on best decision).  
 
The initial questionnaire for participants elicited: 
1) Demographic characteristics: Including age, educational level, previous medical or 
health training and marital status. 
2) Reading the materials: Participants were asked to rate how thoroughly they read the 
information materials they received (response options included: ‘from cover to cover’, 
‘thoroughly’, ‘briefly’, ‘just the relevant parts’ and ‘not at all’).  
3) Decisional conflict:  The Decisional Conflict Scale (DCS) was used to assess 
uncertainty about choosing among alternatives.24 It has four subscales which assess 
 11 
modifiable factors contributing to decisional conflict, including feeling informed, 
being clear about values, feeling supported in decision-making and feeling certain 
about the decision.14
4) Knowledge of genetic testing: Eight true-false items were purposively designed for 
this study and assessed knowledge about the genetic testing process, and the benefits, 
risks and limitations of genetic testing.   
  
5) Multidimensional Measure of Informed Choice (MMIC): This scale classifies 
respondents as having made an informed or uninformed choice. An informed choice is 
one based on relevant knowledge, consistent with the decision maker’s values and 
behaviorally implemented.25
6) Family involvement: Two ‘yes/no’ items assessed whether any other family member 
read the information materials given to the patient and whether other family members 
contributed to their decision-making process. Those who responded ‘yes’ were asked 
to indicate, using Likert-type scales separately for each family member, the extent to 
which they had read the materials (‘from cover to cover’ through to ‘briefly’), and 
their level of involvement in the decision-making process (‘extremely involved’ to ‘a 
little involved’). 
 The measure combines the knowledge test described 
above, a 4-item attitudes scale, and genetic testing decision. As described in the 
scale’s validated scoring instructions, two groups were classified as having made an 
informed choice: those who scored above the sample median on the knowledge scale, 
had a positive attitude towards testing and decided to undergo testing, and those who 
had a good knowledge score, a negative attitude towards testing and did not undergo 
testing. All other women were categorized as having made an uninformed choice.  
7) Impact of Event Scale (IES): The 15-item IES was used to measure the frequency and 
severity of intrusive and avoidant thoughts about being at risk of developing breast 
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and/or ovarian cancer.26 The scale has good psychometric properties in women at 
increased risk of breast cancer.27
8) Hospital Anxiety and Depression Scale (HADS): The HADS is a 14-item self-report 
scale which requires respondents to choose between 4 responses that most closely 
describe how they have been feeling in the past week.
 
28 The scale has been validated 
in cancer patients.29-31
9) Genetic testing decision: One item asked participants about their decision about 
genetic testing at this point in time (ie. 1 week after their first consultation). In order to 
reduce the demand for potentially sensitive information from participants, they were 
not asked about any genetic testing results they had received at either time point. 
  
 
The second questionnaire collected data on measures 2 to 9 described above, as well as the:  
Decision Regret Scale (DRS): The 5-item DRS assesses level of healthcare decision regret, 
and has good internal consistency and validity.32 
 
2.3.3 Data analysis 
Data were analyzed using SPSS 14.033 and STATA 9.2.34 Descriptive statistics were used to 
describe the socio-demographic and other characteristics of the sample. This was followed by 
an ‘intention to treat’ analysis on the effects of the randomized trial of DA provision. As DCS 
and regret scores were highly skewed, these variables were recoded into binary dichotomous 
variables, with participants who received the minimum score for these scales (1.5 for DCS; 0 
for regret) being grouped into the ‘low DCS’ and ‘low regret’ groups respectively. Similarly, 
knowledge was recoded into a categorical variable with three levels (low, medium and high 
knowledge).   
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In order to maximize the usefulness of all data collected and take account of the family-wise 
randomization, observations from the same family were treated as clusters using the method 
described by Williams.35
The analyses used binary logistic regression for dichotomous dependent variables (DCS, 
informed choice, family involvement and regret) and multinomial logistic regression for 
knowledge (a test of proportional odds showed that ordinal regression was not appropriate 
because the effect of the independent variable was not uniform over the 3 levels of the 
dependent variable). Multinomial logistic regression essentially combines 2 binary logistic 
regression analyses, each based on a comparison of two of the levels of the outcome variable 
with the third level, or reference category. Results are reported as Wald’s tests of parameters, 
which allow significance testing using χ
 ALAN, COULD YOU ADD ANOTHER SENTENCE 
SUMMARIZING THE ANALYTIC APPROACH WE TOOK TO CLUSTERED DATA? A 
Bonferroni adjustment for multiple tests was not employed, as we wanted to control for Type 
1 error at a 0.05 level of significance for each dependent variable separately, rather than over 
all dependent variables considered together. Extensive data analysis revealed no significant 
differences between scores for women considering mutation search compared to predictive 
testing on any of the dependent variables. As well, analysis of all two-way interactions 
revealed that the DA did not have a significantly different effect on the two groups of women 
for any dependent variable, so the two groups were combined for the purposes of the 
analyses. 
 
2. All regression models were run separately for each 
dependent variable, and always included time as a covariate and the clinic the woman 
attended as a fixed factor in the models. Thus, each model included dummy codes for clinic, 
group, time and the interaction between group and time. This strategy allowed us to 
incorporate the available data from both time points in the same analysis, as well as account 
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for any potential differences between clinics.  
 
RESULTS 
Response rates and sample 
Figure 2 presents the composition of the study participants. Briefly, 155 women were invited 
to participate in the study, of whom 145 (93.5%) agreed to participate. Of these, 119 returned 
the first questionnaire (82.1%) and 120 returned the second questionnaire (82.8%). Table 1 
presents the participants’ demographic characteristics. There were no important group or 
clinic differences in demographic characteristics nor in any of the clinician reported data, 
indicating that randomization was successful in spreading potential confounding variables 
equally between the groups and across clinics.  
 
-------------------- Insert Fig. 2 about here------------------------------------------------------------- 
 
-------------------- Insert Table 1 about here------------------------------------------------------------- 
 
Clinician report 
Type of genetic test: Sixty-one percent of participants were considering mutation search and 
39% were considering predictive genetic testing (see Table 1). Of those considering 
predictive testing, 66.0% were considering predictive testing after a mutation had been 
identified in their family, and 34.0% comprised of other types of predictive testing situations, 
such as women considering screening for founder mutations and women considering future 
predictive testing in families where a mutation had not yet been identified. There were no 
significant differences between women considering different types of predictive testing on 
any of the dependent variables, so they were combined for further analysis.   
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Participant disease status: Of the 73 participants (60.8%) who had had a previous diagnosis 
of cancer, 67 (91.8%) were affected with breast cancer only, 5 (6.8%) with ovarian cancer 
only and 1 (1.4%) with both breast and ovarian cancer. Of the 52 women who were 
unaffected by cancer, 46 (88.5%) had a 50% mutation carrier risk status (MCR), 4 (7.7%) had 
a 25% MCR, 1 (1.9%) woman had a 12.5% MCR and one (1.9%) had a 100% MCR as she 
was an intervening relative. 
 
Blood drawn: Blood was drawn immediately after the first consultation in 43 (35.8%) cases. 
Having blood drawn was equally distributed in the study groups, with 32.9% of women in the 
DA group having blood drawn after the consultation compared to 34.7% of women in the 
control group (χ2(1)=0.06; P=.814). Giving blood at the first appointment was more common 
in women considering mutation search, with 29 (39.7%) of these women having blood drawn 
on the day of the consultation, compared to 14 (29.8%) of women considering predictive 
testing, although this difference was not statistically significant (χ2(1)=1.23; P=.268).    
 
Participant’s decision: In 113 (94.2%) cases, the clinician’s opinion on the best decision for 
the patient agreed with the participant’s decision one week after the consultation, with only 7 
(5.8%) cases in which the clinician’s opinion did not agree with that of the participant. Of 
these cases, 3 women remained undecided after the consultation, while their clinician 
recommended genetic testing and 4 women decided to undergo testing while the clinician felt 




Reading the materials 
Both the DA and the control pamphlet were read thoroughly before completing questionnaire 
1, with 69.6% of the DA group and 76.2% of the control group reporting having read the DA 
or the control pamphlet ‘from cover to cover’ or ‘quite thoroughly’. Women who had blood 
drawn on the day of their consultation were less likely to thoroughly read the educational 




All dependent variable mean scores and proportions are presented in Table 2. 
 
-------------------- Insert Table 2 about here------------------------------------------------------------- 
 
Main effects 
Overall, there was no significant difference between decisional conflict full-scale scores in 
women who received the DA compared to those who received the control pamphlet 
(χ2(1)=0.01;  P=0.937). However, the DA had a significant effect on scores on the informed 
subscale, such that women who received the DA were significantly more likely to be in the 
‘informed’ group than women who received the control pamphlet (χ2(1)=4.86;  P=0.028). The 
DA had no effect on the remaining subscales, including support (χ2(1)=2.2;  P=0.138), 
certainty (χ2(1)= 0.70; P=0.401) and clear values (χ2(1)= 2.52; P=0.113). 
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Interaction with having blood drawn 
There was no significant interaction between choosing to have blood drawn on the day of the 
consultation and the effect of the DA on decisional conflict full-scale score, nor on three of 
the subscale scores (DCS: χ2(1)= 0.21; P=0.644; Informed: χ2(1)= 1.63; P=0.201; Support: 
χ2(1)= 0.26; P=0.608; Certain: χ2(1)= 0.64; P=0.422). However, there was a significant 
interaction between choosing to have blood drawn and group for the clear values subscale 
(χ2(1)= 4.01; P=0.045), such that women in the DA group who did not have blood drawn on 
the day of their consultation had significantly clearer values with regards to genetic testing 
than women who received the control pamphlet (χ2(1)= 6.67; P=0.022). In contrast, the DA 
had no effect on mean clear values scores for women who did have blood drawn on the day of 
their consultation (χ2(1)= 0.61; P=0.433). See Figure 3. 
 




The main effects model showed that the DA significantly improved knowledge at both time 
points (χ2(2)= 6.82; P=0.033). More specifically, the odds of women who received a DA 
being in the high knowledge group (relative to the low knowledge group) were more than 
twice as high as those for women in the control group (RRR=2.73; P=0.015) (see Figure 4). 
 
-------------------- Insert Fig. 4 about here------------------------------------------------------------- 
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Interaction with having blood drawn 
There was no significant interaction between choosing to have blood drawn on the day of the 
consultation and the effect of the DA on knowledge score (χ2(2)= 5.51; P=0.064).  
 
Informed choice 
The effect of the DA on the measure of informed choice was not significant (χ2(1)=1.06; 
P=0.304), nor was there any significant interaction effect of having blood drawn on the day 
of the consultation (χ2(1)=0.20; P=0.657).   
 
Family involvement 
The majority of women reported sharing the information materials they received with other 
family members, particularly by 6 months after their consultation (see Table 2). Logistic 
regression with the dichotomous variable (‘information shared with any family member’ 
versus ‘not shared with any family member’) showed that women who received a DA were 
less likely to share the materials they received, relative to women who received the control 
pamphlet (χ2(1)=8.78; P=0.003). There was no significant group difference in the level of 
perceived family involvement in decision-making (χ2
Participants named their spouse or partner most often as the family member who had read the 
information materials they received and had contributed to their decision-making process. By 
time 2, 40.3% of women in the DA group and 46.0% of women in the control group reported 
that their spouse or partner had read the information materials they received at their 
consultation. As well, 38.6% of women in the DA group and 28.6% of women in the control 
(1)=0.81; P=0.368). 
 
-------------------- Insert Table 2 about here------------------------------------------------------------- 
 
 19 
group reported that their spouse or partner had contributed to their decision-making about 
genetic testing.  
 
Psychological variables 
The DA did not appear to affect women’s reported levels of psychological distress, with no 
significant group differences in intrusive and avoidant thoughts, anxiety or depression.  
 
Regret 
Logistic regression revealed no significant group differences in women’s reported regret 
about their genetic testing decision six months after their consultation (χ2(1)=2.70; P=0.100).  
 
Genetic testing uptake 
Genetic testing uptake was high, with 105 out of 114 (92.1%) participants eligible for genetic 
testing after their first consultation deciding to undergo testing. Of the 6 women who were 
awaiting the results of a relative’s genetic test, 4 were still waiting for the results 6 months 
post-consultation, and 2 had become unable to undergo genetic testing as a mutation was not 
identified in their affected family member. Of the remaining 9 women, 6 (5.0%) reported 
being undecided about genetic testing and 3 (2.5%) women reported that they did not want to 
undergo genetic testing. Apart from the 2 women whose family member’s results became 
available, all participants’ genetic testing decisions were stable over the time period 6 months 





This randomized trial revealed three significant main effects of a DA for women considering 
genetic testing for breast/ovarian cancer risk: women who received the DA had significantly 
higher knowledge scores, felt more informed about genetic testing and were less likely to 
report that other family members had read the information materials they received, compared 
to those in the control condition. Moreover, for women who did not have blood drawn on the 
day of their consultation, receiving the DA also helped them to clarify their values with 
regards genetic testing. Consistent with previous research, the DA did not appear to affect 
women’s psychological functioning, their actual genetic testing decision, nor their scores on 
the certainty and feeling supported subscales of the decisional conflict scale.21,36 
 
In general, women were knowledgeable and felt confident about their genetic testing decision, 
regardless of whether or not they received the DA. This can be seen in the highly skewed 
knowledge, decisional conflict and regret scores reported in Table 2. Reflecting this, we 
report a high genetic testing uptake rate of 92.1%, confirming previous research showing that 
women who approach familial cancer clinics tend to be more interested in genetic testing than 
women with a family history of breast/ovarian cancer in the general population and in 
genetics research settings.37-40
In Australia, where, as a general rule, genetic testing decisions are made only after at least one 
consultation with a genetic counselor and/or clinical geneticist or oncologist, it is perhaps not 
surprising that knowledge and certainty levels are high in this population. Despite this high 
level of face-to-face education and support, the DA was still able to add value over and above 
the consultation. Further research on the effectiveness of the DA in women who decide not to 




through referral from another medical service or in the public arena) would provide valuable 
information about the effect of the DA on women who may have lower knowledge and 
certainty levels than the group who do currently attend the clinics. Indeed, recent research 
suggests that women who do not attend familial cancer clinics after receiving a referral from 
their breast cancer treatment team list more cons of genetic testing than those who do attend 
after their referral.41  
 
The finding that women who did not give blood on the day of their consultation were more 
likely to benefit from the DA in terms of having clearer values is consistent with the data 
showing that they were more likely to read the information materials they received than 
women who did have blood drawn on the day of their consultation. Indeed, a recent 
evaluation of a French genetic testing information booklet showed a significant dose-response 
relationship, such that women who read the booklet most thoroughly experienced the most 
benefits from the tool.42
Our data raise an important question about when the decision about genetic testing is made by 
most women. It is possible that a patient who changes their mind about genetic testing after 
having blood drawn may choose not to receive their test results, implying that the theoretical 
point of decision-making is actually at the receipt of test results.
  
 
11 In practice, however, none 
of the women in our study changed her genetic testing decision in the six months post- 
consultation, suggesting that the actual decision-making point for the individual is at, or even 
before, the drawing of blood. This raises important considerations for DA developers, who 
generally seek to expose the patient to DAs before they feel they have made their decision. A 
second randomized controlled trial of this DA is currently underway, using the DA as a 
communication aid during genetic counseling. Data from this trial will speak to the impact of 
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using a DA during counseling to ensure that all participants have the opportunity to use the 
tool before having blood drawn. 
 
The family involvement data warrants further discussion. Firstly, the data revealed a novel 
finding: that women who received the tailored DA were less likely to share the tool with their 
family members. We did not ask about reasons for sharing or not sharing the information, but 
it is possible that women did not want to disclose the unique information contained in it, 
including the personalized risk information entered by their clinician and the personal 
worksheet, which was completed by more than 70% of the women who received the DA. 
Alternatively, the DA may have been less likely to be shared with other family members due 
to its length. 
 
Secondly, of those women who did share the DA or control pamphlet with their family, the 
family member most likely to be named as having read the materials, and having contributed 
to the decision-making process, was the participant’s spouse or partner. This data supports 
recent research emphasizing the importance of considering the spouse within the familial 
cancer setting.43,44 Traditionally, given that they are not blood relatives of the patient and 
hence not at genetic risk, the role of the spouse has received little attention in the familial 
cancer clinic process, but they clearly play a critical role in patients’ decision-making about 
genetic testing. Given that the DA was less likely to be shared with family members than the 
control pamphlet, clinicians should consider providing additional, specific information for 




It was not possible to collect a baseline (ie. pre-counseling) assessment of participants 
because; i) it is often not possible to establish a patient’s eligibility for genetic testing until a 
full family history has been collected and verified during the first consultation; and ii) the lead 
time between patients’ contacting the clinic and their first appointment is often very short (ie. 
2-3 days), meaning that many baseline questionnaires would have not been completed before 
the consultation. However, given that the participants were randomized to receive the DA or 
the control pamphlet, any pre-counseling characteristics in patients should have been evenly 
distributed across both groups. 
 
It was also not possible for clinicians to be blinded to the randomization status of the 
participants because the majority of clinicians expressed a preference for entering 
personalized risk information into the DA. However, we attempted to minimize the impact of 
this by instructing clinicians to open the recruitment package at the end of the consultation. It 
was also not possible to control the content of the consultation for each patient, or the 
additional information materials they received from their clinic or from other external sources 
such as the world-wide web. However, any additional sources of information should have 
been evenly distributed across both groups. As well, it is possible that some participants 
completed their questionnaires before reading their allocated information materials, despite 
clear written and verbal requests not to do so. The data provided on reading the materials 
however, showed that the large majority of participants reported that they did read the 
materials before completing the questionnaire. 
 
The current DA did not cover the needs of all familial cancer clinic patients. Men considering 
genetic testing for breast/ovarian cancer risk for example, need to consider a unique set of 
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issues in their decision-making process about genetic testing, including the implications of 
their test result for their own health as well as the risks that may be passed on to their 
daughters. Similarly, women affected with breast cancer considering predictive testing may 
have different informational needs with regards to issues such as their risk of developing 
further cancers, either of the breast or ovaries. Indeed, it is worthwhile considering the 
information needs of each patient as an individual, as sometimes a ‘one size fits all’ approach 
may not fully utilize the benefits of a decision support tool such as this. It may be more 
beneficial, for example, for clinicians to use DAs during, or even before (when eligibility for 
testing has been confirmed and there is a reasonable time available before the appointment), 
their consultations for some patients in order ensure that they are exposed to decision support 
tools before making their decision about testing.45 
 
Finally, the women in this study tended to have a higher education level than the general 
population, with 63% having a post-school qualification, compared to 52% of the general 
population.46 Although this phenomenon has been identified in previous studies in the familial 
cancer setting,38 the discrepancy between the general and clinical population appears to be 
narrowing. For example, earlier Australian data reported post-school qualifications in over 
70% of women attending familial cancer clinics,47,48
Use of a genetic testing DA in conjunction with genetic counseling can increase women’s 
actual knowledge and feelings of being informed about genetic testing for breast/ovarian 
cancer risk. Family members who attend a familial cancer clinic might benefit from each 
receiving their own information materials, as patients may be less likely to share information 
 suggesting that the numbers of women 




tools about genetic testing if they are personalized. Finally, it is important to consider the 
needs and concerns of the spouse or partner in the familial cancer setting.       
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Figure 1. Flowchart detailing the process of care and recruitment. 
Figure 2. Participant flow. 
Figure 3. Interaction between clear values score and whether blood was drawn at first 
consultation.  























































Figure 1. Flowchart detailing the process of care and recruitment. 
  
First consultation with 
familial cancer clinic. 
At end of consultation, the 
clinician invites patient to 
participate in the study. 
Continue with 
standard care. 
Clinician gives patient a 
randomized opaque envelope, and 
opens it in front of them. 
Patient consents Patient declines 
If the patient receives the DA, the 
clinician enters relevant tailored 
information into DA (eg. 
personalized risk estimate). 
Some patients decide to 
have blood drawn for 
genetic testing. 
Most patients go home to 
consider their genetic 
testing decision. 
Patients’ first opportunity to 
read the information materials 
they received, and complete and 






Figure 2. Participant flow. 
 
 
Assessed for eligibility and invited 
to participate (n=155) 
Declined (n=10) 
   Too busy (n=3) 
    Ill health (n=4) 
    Not interested in study (n=1) 





Allocated to control (n=72) 
Returned Questionnaire 1 (n=63) 
Did not return Q1 (n=9) 
    Withdrew before Q1 (n=3)               
    Non-contactable (n=6)     
 
Allocated to intervention (n=73) 
Returned Questionnaire 1 (n=56) 
Did not return Q1 (n=17) 
   Withdrew before Q1 (n=5) 




Returned Questionnaire 2 (n=57) 
Did not return Q2 (n=16) 
    Non-contactable (n=16) 
    Withdrew after Q1 (n=0) 
Returned Questionnaire 2 (n=63) 
Did not return Q2 (n=9) 
    Lost to follow up (n=8) 




6 mth follow up  
Analysis 
Analysed (n=57) 
NB:A total of 51 women completed 
both Q1 & Q2, 5 completed Q1 only 
and 6 completed Q2 only     
Analysed (n=63) 
NB: A total of 60 women completed 
both Q1 & Q2, 3 completed Q1 only 
and 3 completed Q2 only     
 
Clinic enrolment numbers 
Prince of Wales Hospital: 34 
Westmead Hospital: 36 
Peter McCallum Cancer Inst: 30 
St Vincent’s Hospital: 23 

































Figure 3. Interaction between mean clear values scores and whether blood was drawn at first 
consultation.  
 * Minimum, or ideal, score is 1.5. Higher scores represent less clear values. 
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Table 1. Demographic characteristics of participants  
Table 2. Dependent variable mean scores 
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Table 1. Demographic characteristics of participants (n=120) 




Age  Mean: 45.8 years 
Range: 21-73 years 
49.6 years 
Range: 22-75 years 
Type of genetic test Mutation search 32 (56.1%) 41 (65.1%) 
Predictive testing- mutation 
identified 
17 (29.9%) 14 (25.8%) 
 
Other predictive testing 8 (14.0%) a 8 (12.7%) 
Disease status  Affected by cancer 32 (56.1%) 41 (65.1%) 
Unaffected by cancer 25 (43.9%) 22 (34.9%) 
Education level High school only 15 (26.3%) 23 (36.5%) 
Certificate/diploma 21 (36.8%) 19 (30.2%) 
Undergraduate degree 9 (15.8%) 10 (15.9%) 
Postgraduate degree 12 (21.1%) 11 (17.5%) 
Any medical/health 
training? 
No 42 (73.7%) 47 (74.6%) 
Yes 15 (26.3%) 16 (25.4%) 
Marital status Never married 12 (21.1%) 6 (9.5%) 
Married/de facto 37 (64.9%) 43 (68.3%) 
Widowed 0 (0%) 3 (4.5%) 
Separated/divorced 8 (14.0%) 11 (17.5%) 
Biological children No children 13 (22.8%) 15 (23.8%) 
Yes 44 (77.2%) 48 (76.2%) 
 
a This group is comprised of unaffected women considering predictive testing for Jewish founder mutations or 
predictive testing where a family-specific mutation has not yet been identified.
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Table 2. Dependent variable mean scores and proportions (s.d. in brackets) 
  N DA group Control group 
Knowledge of genetic testing  Time 1 116 7.19 (1.01)* 6.74 (1.32)* 
Time 2 119 7.14 (0.88)* 6.68 (1.21)* 
Decisional Conflict Scale (DCS) Time 1 117 1.64 (0.24) 1.68 (0.32) 
Time 2 119 1.65 (0.39) 1.66 (0.35) 
DCS: Informed subscale Time 1 117 1.57 (0.30)* 1.69 (0.40)* 
 Time 2 120 1.60 (0.39)* 1.65 (0.37)* 
DCS: Clear values subscale Time 1 119 1.62 (0.37) 1.79 (0.62) 
 Time 2 120 1.72 (0.66) 1.75 (0.60) 
DCS: Supported subscale Time 1 119 1.71 (0.49) 1.58 (0.24) 
 Time 2 119 1.66 (0.40) 1.62 (0.33) 
DCS: Certainty subscale Time 1 117 1.72 (0.57) 1.69 (0.61) 
 Time 2 119 1.71 (0.57) 1.67 (0.55) 
Decisional Regret Scale (DRS) ** Time 2 103 7.04 (12.12) 6.39 (13.68) 
Proportional data for dichotomous variables (%) 
Multidimensional Measure of Informed Choice 
(MMIC) 
Time 1 113 51.9% ‘informed’ 39.3% ‘informed’ 
Time 2 110 47.2% ‘informed’ 43.9% ‘informed’ 
Did any family member read the information 
materials? 
Time 1 120 32.1% ‘yes’* 55.6% ‘yes’* 
Time 2 120 54.4% ‘yes’* 76.2% ‘yes’* 
Did any family member contribute to decision-
making? 
Time 1 120 47.4% ‘yes’ 63.5% ‘yes’ 
Time 2 120 54.4% ‘yes’ 54.0% ‘yes’ 
Genetic testing uptake** Time 1 114 94.3% ‘yes’ 90.2% ‘yes’ 
 Time 2 116 94.4% ‘yes’ 91.8% ‘yes’ 
* p<.05 
 
** Some women did not answer the Regret Scale or uptake questions because they either remained undecided 
about genetic testing, or were awaiting the results of a relative’s genetic test and were therefore unable to 
undergo testing at this point. 
